Alnylam's Phase III Results For Vutrisiran Are 'Foundation' For Amyloidosis Expansion

FDA Filing Anticipated In Early 2021

 
• By Alaric DeArment
nerve cells, concept for neurodegenerative and neurological disease
Alnylam announces positive Phase III results for vutrisiran in hATTR amyloidosis with polyneuropathy. • Source: Shutterstock

More from R&D

More from Scrip